Skip to main content
ROQUEFORT THERAPEUTICS PLC logo

ROQUEFORT THERAPEUTICS PLC — Investor Relations & Filings

Ticker · ROQ ISIN · GB00BMDQ2T15 LEI · 254900P4SISIWOR9RH34 IL Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2025-06-27 M&A Activity
Country GB United Kingdom
Listing IL ROQ

About ROQUEFORT THERAPEUTICS PLC

https://www.roquefortplc.com/

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Recent filings

Filing Released Lang Actions
Lyramid SPA Extension
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated '27 June 2025'. It discusses an extension to a binding share purchase agreement (SPA) for the sale of a subsidiary, which is a material corporate transaction. The text explicitly states, 'This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (UK MAR).' The document concludes with contact details and a footer indicating it is provided by 'RNS, the news service of the London Stock Exchange.' This structure and content strongly indicate a general regulatory announcement disseminated via the RNS system, which aligns best with the 'Regulatory Filings' category (RNS), as it is not a specific financial report (like 10-K or IR), a management discussion (MDA), or a specific transaction report like Director's Dealing (DIRS) or Share Issue (SHA). It is a general corporate update disseminated through the official regulatory news service.
2025-06-27 English
Results of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states 'Results of AGM' and details the poll results for various resolutions presented to shareholders at the Annual General Meeting ('AGM'). This content directly corresponds to the reporting of voting outcomes following a shareholder meeting. The appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the core content is the *results* of the vote, not general AGM presentation materials (AGM-R).
2025-06-26 English
Issue of Equity
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Roquefort Therapeutics regarding the issuance of new ordinary shares to settle debts with a former employee. It details the number of shares issued, the expected admission to trading on the London Stock Exchange, and the resulting total voting rights. This falls squarely under the definition of a share issue or capital change announcement.
2025-06-13 English
Notice of Annual General Meeting
AGM Information Classification · 98% confidence The document explicitly states 'Notice of Annual General Meeting' and provides the date, time, and location for the AGM. It also mentions that the Notice and Proxy Forms 'can be downloaded' from the company website. Since this is an announcement about the AGM materials rather than the full presentation or voting results themselves, it aligns best with the 'AGM Information' category (AGM-R). Although it is a short announcement, the specific subject matter (Notice of AGM) overrides the general 'Report Publication Announcement' fallback.
2025-06-02 English
Extension of Convertible Loan Notes
Regulatory Filings Classification · 98% confidence The document is a short announcement disseminated via RNS (RNS Number: 8808J) from Roquefort Therapeutics PLC. It details an extension of the maturity date for Convertible Loan Notes (CLNs) and includes standard regulatory boilerplate language regarding UK MAR and RNS distribution. Since it is a brief, specific corporate action announcement distributed through a regulatory news service, and it does not fit the criteria for a full financial report (10-K, IR, ER) or a specific event material (AGM-R, IP), it falls best under the general Regulatory Filings category (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2025-05-23 English
2024 Annual Report
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-05-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.